Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study

Introduction: During the 22-week core LINC 2 study, the oral 11β-hydroxylase inhibitor osilodrostat normalized mean urinary free cortisol (mUFC) in 79% (15/19) of patients with Cushing’s disease. This report describes long-term LINC 2 efficacy and safety results following an optional extension. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleseriu, Maria, Biller, Beverly M K, Bertherat, Jerome, Young, Jacques, Arnaldi, Giorgio, O’Connell, Paul, Izquierdo, Miguel, Pedroncelli, Alberto M, Pivonello, Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090717/
http://dx.doi.org/10.1210/jendso/bvab048.1063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090717/
http://dx.doi.org/10.1210/jendso/bvab048.1063

Ejemplares similares